Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 15/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.71 |
| ▸ | TSHR | P16473 | 3/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.71 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.71 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.71 |
| ▸ | HTR2A | P28223 | 2/20 | 0.71 |
| ▸ | HTR2C | P28335 | 2/20 | 0.71 |
| ▸ | HRH1 | P35367 | 2/20 | 0.71 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.71 |
| ▸ | DRD3 | P35462 | 2/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.71 |
| ▸ | HTR2B | P41595 | 2/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.71 |
| ▸ | KLF10 | Q13118 | 2/20 | 0.71 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30501482 | 1.00 | SLC6A4 (0.71) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL8082370 | 1.00 | SLC6A4 (0.71) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4625001 | 0.99 | SLC6A2 (0.71) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Oxalic Acid SCHEMBL4623443 | 0.95 | SLC6A4 (0.64) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9347671 | 0.84 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9348316 | 0.84 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9347628 | 0.84 | SLC6A4 (0.75) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6823348 | 0.84 | NOS2 (0.50) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12841456 | 0.84 | NOS2 (0.50) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2738780 | 0.84 | SLC6A2 (0.79) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379492-B1 | INHIBITOR OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | claimed |
| US-20210401790-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED, INC. (DELAWARE) | 2021-12-30 | — | — | US | disclosed |
| WO-2012020418-A1 | NOVEL POLYMORPHS OF 4-HYDROXY ATOMOXETINE HYDROCHLORIDE | MATRIX LABORATORIES LTD (IN) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011027359-A2 | NOVEL PROCESS FOR THE PREPARATION OF 4-HYDROXY ATOMOXETINE | MATRIX LABORATORIES LTD (IN) | 2011-03-10 | — | — | WO | disclosed |
| US-7384983-B2 | Inhibitor of monoamine uptake | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384983-B2 | Inhibitor of monoamine uptake | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| US-7384983-B2 | Inhibitor of monoamine uptake | ELI LILLY AND COMPANY (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1379492-B1 | INHIBITOR OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1379492-B1 | INHIBITOR OF MONOAMINE UPTAKE | LILLY CO ELI (US) | 2008-05-21 | — | — | EP | disclosed |
| US-20050209341-A1 | Inhibitor of monoamine uptake | MATTIUZ EDWARD L | 2005-09-22 | — | — | US | disclosed |
| US-20040082666-A1 | Inhibitor of monoamine uptake | MATTIUZ EDWARD LOUIS (US) | 2004-04-29 | — | — | US | disclosed |
| EP-1379492-A1 | INHIBITOR OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002070457-A1 | INHIBITOR OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082666-A1 | Inhibitor of monoamine uptake | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A2 2/4885CYP1A2 376/4885 |
| US-20050209341-A1 | Inhibitor of monoamine uptake | SLC18A2, SLC6A2, SLC18A3 | SLC6A4 4/4885SLC6A2 2/4885CYP1A2 376/4885 |
| US-20210401790-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | HCRTR2, CHRM3, CHRM2 | SLC6A4 193/4885SLC6A2 164/4885CYP1A2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.